Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy. To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates (https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data. We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS) (https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates at the Public Use Microdata Areas (PUMA) level using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center(https://mcdc.missouri.edu/applications/geocorr2014.html). PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations. The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31.. PUMA COVID-19 Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-Public-Use-Microdat/djj9-kh3p

Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy. To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates(https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data. We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS)(https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates in more granular areas using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). Public Use Microdata Areas (PUMA) level – PUMAs are geographic areas within each state that contain no fewer than 100,000 people. PUMAs can consist of part of a single densely populated county or can combine parts or all of multiple counties that are less densely populated. The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31. County and State Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-County-and-local-es/q9mh-h2tw

Estimates of vaccine sentiment with breakdowns by different population groups. Analysis based on the Opinions and Lifestyle Survey.

In December 2020, a survey carried out in the UK found that 61 percent of respondents who indicated they did not want to receive a vaccination against COVID-19 are unwilling to do so because they are worried about unknown side effects of the vaccine. Furthermore, 15 percent of those skeptical of receiving the vaccine don't believe it will be effective. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates using the most recently available federal survey data.

The dataset was used in a cross-sectional study aimed at investigating, among Italian university students, the acceptance and uptake of the COVID-19 vaccine as well as the factors that led to these outcomes. The secondary goal was to pro-vide insight for future interventions by shedding light on the potential barriers to COVID-19 vaccine access.The information is collected through an online questionnaire that is filled in by respondents. The online survey was sent via institutional email. An anonymous and structured questionnaire was used. The survey questions covered the following topics: socio-demographic characteristics (8 closed-ended with multiple answers and open-ended questions); general information (i.e., personal or family members' history of COVID-19 and the severe side effects they experienced) (5 questions with a “yes/no” response format); general knowledge about vaccines and COVID-19 vaccine (4 questions with a “true/false/do not know” response format); fear and attitudes towards COVID-19 vaccine (8 questions with true/false/do not know response format and closed-ended with five-point Likert scale response format); practices related to COVID-19 vaccine (7 items on a five-point Likert scale response format); sources of information and trust in the information received about COVID-19 vaccines (4 items, closed-ended with multiple answers and “yes/no” response format).

Analysis of ‘Vaccine Hesitancy for COVID-19: Public Use Microdata Areas (PUMAs)’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/0cbb7619-3ce8-41ab-9dd7-ca4397d96efa on 27 January 2022.

--- Dataset description provided by original source is as follows ---

Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy.

To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates(https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data.

We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS)(https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates in more granular areas using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). Public Use Microdata Areas (PUMA) level – PUMAs are geographic areas within each state that contain no fewer than 100,000 people. PUMAs can consist of part of a single densely populated county or can combine parts or all of multiple counties that are less densely populated.

The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31.

County and State Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-County-and-local-es/q9mh-h2tw

--- Original source retains full ownership of the source dataset ---

Data from the global South show higher COVID-19-related mortality in children compared to the North. Parents’ willingness to vaccinate their children once COVID-19 vaccines are available is poorly documented. We assessed parents’ willingness to vaccinate their children in the DRC. A year after the vaccination program started, we conducted a population and online-based cross-sectional study, using the WHO modified Behavior and Social Drivers questionnaire among parents and caregivers in the eastern DRC. We performed Modified Poisson regressions to determine factors associated with vaccine hesitancy and outright refusal, focusing on the intention to vaccinate one’s children as our primary outcome. Of the 1709 respondents aged 38 years, 82.56% were unwilling to vaccinate their children, of which 26.80% were hesitant and 55.76% were outright refusals. Drivers of hesitancy were religious refusal of vaccine, non-healthcare status, and caregiver beliefs about vaccine unsafety. Independent predictors of refusal were religious refusal of vaccine, neither healthcare nor student status and belief about vaccine effectiveness, unsafety, and distrust. In addition, both hesitancy and refusal to vaccinate one’s children were driven by not being ready to get vaccinated if recommended or mandated. In contrast, parents’ and caregivers’ trust in the government and readiness to vaccinate themselves reduced hesitancy and outright refusal to vaccinate one’s children, respectively. Briefly, COVID-19 vaccine hesitancy and outright refusal in eastern DRC are influenced by individual (subjective convictions) and system-level factors (government confidence, mandate trust). It is important to address these issues to improve vaccine coverage during disease outbreaks and mitigate public health risks.

Dataset from the article Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. 'Vaccine hesitancy' among university students in Italy during the COVID-19 pandemic. Eur J Epidemiol. 2020 Aug;35(8):781-783. doi: 10.1007/s10654-020-00670-z. Epub 2020 Aug 6. PMID: 32761440; PMCID: PMC7409616.

Abstract

The debate around vaccines has been in the spotlight over the last few years in Europe, both within the scientific community and the general public debate. In this regard, the case of the Italian vaccination debate is particularly worrying given that Italy has been one of the European countries with the highest number of measles cases in the recent past. According to this scenario, we conducted a cross-sectional study on a convenience sample of Italian university students aimed at: (1) exploring their attitudes towards a future vaccine to prevent COVID-19 and; (2) evaluating the impact of the university curricula (healthcare vs. non-healthcare curricula) on the intention to vaccinate. Descriptive analysis on the 735 students that answered to the question on the intention to vaccinate showed that 633 (86.1%) students reported that they would choose to have a vaccination for the COVID-19 coronavirus; on the other side, 102 (13.9%) students reported that they would not or be not sure to vaccine (low intention to vaccinate). This means that in our sample more than one student out of 10 shows low intention to vaccinate (vaccine hesitancy). Furthermore, when running analysis comparing healthcare students versus non-healthcare students we found no significant differences in responses' percentage distribution (p = .097). Understanding the student's perspective about the future COVID-19 vaccine and supporting their health engagement and consciousness may be useful in planning adequate response and multidisciplinary educational strategies-including the psychological perspective on vaccine hesitancy underlying factors - in the post-pandemic period.

In 2024, around 1,185 petitions were filed with the United States National Injury Compensation Program (VICP) seeking compensation for injury or death caused by vaccines. However, just because a petition was filed seeking compensation for injury or death due to a vaccination does not mean that compensation was awarded. Over half of all such petitions filed in the U.S. since 1988 have been dismissed, and in 60 percent of cases in which compensation was awarded it was still not determined whether the alleged vaccine caused the alleged injury. The impact of vaccinations Vaccinations in the United States have had a significant impact on infectious diseases. For example, as of 2017, there are only about 120 new cases of measles per year, compared to over half a million annual cases before the use of vaccination. Vaccinations in the U.S. have also greatly decreased the number of annual cases of hepatitis A and B, rubella, and tetanus. COVID-19 vaccination hesitancy Vaccine hesitancy is a persistent issue in the United States. The issue became especially pertinent during the COVID-19 pandemic in which many people in the United States expressed reluctance to getting a COVID-19 vaccination. In December 2020, 59 percent of adults in the United States who stated they would definitely not or probably not get a COVID-19 vaccine said so because they were worried about possible side effects, while 55 percent said they probably wouldn’t get a COVID-19 vaccination because they do not trust the government to make sure the vaccine is safe and effective. Shockingly, one survey found that even 29 percent of health care workers stated they would probably or definitely not get a COVID-19 vaccine.

We sought in-depth understanding on the evolution of factors influencing COVID-19 booster dose and bivalent vaccine hesitancy in a longitudinal semi-structured interview-based qualitative study. Serial interviews were conducted between July 25th and September 1st, 2022 (Phase I: univalent booster dose availability), and between November 21st, 2022 and January 11th, 2023 (Phase II: bivalent vaccine availability). Adults (≥18 years) in Canada who had received an initial primary series and had not received a COVID-19 booster dose were eligible for Phase I, and subsequently invited to participate in Phase II. Twenty-two of twenty-three (96%) participants completed interviews for both phases (45 interviews). Nearly half of participants identified as a woman (n = 11), the median age was 37 years (interquartile range: 32–48), and most participants were employed full-time (n = 12); no participant reported needing to vaccinate (with a primary series) for their workplace. No participant reported having received a COVID-19 booster dose at the time of their interview in Phase II. Three themes relating to the development of hesitancy toward continued vaccination against COVID-19 were identified: 1) effectiveness (frequency concerns; infection despite vaccination); 2) necessity (less threatening, low urgency, alternate protective measures); and 3) information (need for data, contradiction and confusion, lack of trust, decreased motivation). The data from interviews with individuals who had not received a COVID-19 booster dose or bivalent vaccine despite having received a primary series of COVID-19 vaccines highlights actionable targets to address vaccine hesitancy and improve public health literacy.

A questionnaire survey for parents of children under 5 years of age was conducted to analyze vaccine hesitancy with the 13-valent pneumococcal conjugate vaccine (PCV13) in Shanghai, China. A total of 892 valid questionnaires were collected. Descriptive statistical methods, Chi-square test and effect size of Cohen were used. Among participants, 421 (48.8%) had children who had been vaccinated with PCV13 before the survey while 227 (26.73%) planned vaccination with PCV13 in the future. The main reasons for not receiving vaccination were the fear of adverse reactions (79, 26.7%), beyond vaccination age (69, 23.3%), and no need to vaccinate (44, 14.9%). Reducing vaccine hesitancy and increasing vaccination willingness can be achieved through health interventions, lower vaccine prices, and the adjustment of vaccination strategies.

Survey-based data on "Determinants of COVID-19 vaccine hesitancy in university students and support staff in Pakistan: a machine learning and statistical analysis"

According to a survey from October 2020, three quarters of adults aged 65 and older get a flu shot every year. This statistic shows the percentage of adults aged 50 and older in the United States who get an influenza vaccination every year, sometimes, or never as of October 2020.

COVID-19 vaccine is regarded as the most promising means of limiting the spread of or eliminating the pandemic. The success of this strategy will rely on the rate of vaccine acceptance globally. The study aims to examine the factors that influence COVID-19 vaccine acceptance, intention, and hesitancy. PubMed was searched comprehensively for articles using the keyword “COVID-19 vaccine surveys.” Of the 192 records, 22 studies were eligible for the review. Eighty-two percent of these studies were conducted among the general population. Gender, age, education, and occupation were some of the socio-demographic variables associated with vaccine acceptance. Variables such as trust in authorities, risk perception of COVID-19 infection, vaccine efficacy, current or previous influenza vaccination, and vaccine safety affected vaccine acceptance. Globally, in March 2020, the average vaccine acceptance observed was 86% which dropped to 54% in July 2020 which later increased to 72% in September 2020. Globally, the average rate of vaccine hesitancy in April 2020 was 21%, which increased to 36% in July 2020 and later declined to 16% in October 2020. Large variability in vaccine acceptance and high vaccine hesitancy can influence the efforts to eliminate the COVID-19. Addressing the barriers and facilitators of vaccines will be crucial in implementing effective and tailored interventions to attain maximum vaccine coverage.

Context

In 2020 the whole world was struck with a global pandemic. Everywhere around the globe all the cities went under lockdown. Our only hope out from this pandemic are vaccines and when they were introduced people were hesitancy to take the vaccine.

Acknowledgements

This data was collected from data.gov

This dataset tracks the updates made on the dataset "Vaccine Hesitancy for COVID-19" as a repository for previous versions of the data and metadata.

Assessing the prevalence of COVID-19 vaccine hesitancy before and during vaccine rollout in the United States, China, Taiwan, Indonesia, India, and Malaysia. The information in this deposit includes data collected in March 2020 through April 2021, along with a codebook explaining how each of the variables in the datasets were derived from each survey.

A published data note explaining the data in more depth will be made available in the future.

This dataset contains data collected between November 15, 2021, and March 15, 2022. Demographic variables, data on vaccinated people, reasons for not getting vaccinated, and responses to items on the Vaccination Attitudes Examination (VAX) scale are included. Although the language of the open answers is Spanish, the name of the variables and the value labels are written in English to facilitate their understanding.

The Coronavirus Disease 2019 (COVID-19) pandemic has disproportionately impacted people who use drugs (PWUD). This study explored relationships between drug use, COVID-19 testing, vaccination, and infection. This cross-sectional study was conducted in Miami, Florida between March 2021 and October 2022 as part of the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative and the Miami Adult Studies on HIV (MASH) cohort. Users of cannabis, cocaine/crack, heroin/fentanyl, methamphetamines, hallucinogens, and/or prescription drug misuse in the previous 12 months were considered PWUD. Sociodemographic data, COVID-19 testing history, and vaccination-related beliefs were self-reported. Vaccinations were confirmed with medical records and positivity was determined with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. Statistical analyses included chi-square tests and logistic regression. Of 1,780 participants, median age was 57 years, 50.7% were male, 50.2% Non-Hispanic Black, and 66.0% reported an annual income less than $15,000. Nearly 28.0% used drugs. PWUD were less likely than non-users to self-report ever testing positive for SARS-CoV-2 (14.7% vs. 21.0%, p = 0.006). However, 2.6% of participants tested positive for SARS-CoV-2, with no significant differences between PWUD and non-users (3.7% vs. 2.2%, p = 0.076). PWUD were more likely than non-users to experience difficulties accessing testing (10.2% vs. 7.1%, p = 0.033), vaccine hesitancy (58.9% vs. 43.4%, p = 0.002) and had lower odds of receiving any dose of a COVID-19 vaccine compared to non-users (aOR, 0.63; 95% CI, 0.49–0.81; p